Teva Pharmaceutical Industries (NYSE: TEVA) plans to double the volume of production at its pharmaceutical factory in Russia’s Yaroslavl up to 500 million tablets per year, compared to the current 250 million, according to recent statements of the Yaroslavl regional authorities.
According to Anna Yarvits, general director of Teva Russia, the company puts big hopes on the Russian pharmaceutical market, considering it as one of the most promising for its further growth.
Other details of the project, as well as planned investments, are not disclosed.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze